Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA

被引：25

作者：

Cleland, JGF ^{[1
]}

Coletta, AP ^{[1
]}

Clark, AL ^{[1
]}

Velavan, P ^{[1
]}

Ingle, L ^{[1
]}

机构：

[1] Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull HU15 5JQ, Yorks, England

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2005年 / 7卷 / 05期

关键词：

darbepoetin alfa; ECHOS; ASCOT-BPLA;

D O I：

10.1016/j.ejheart.2005.07.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article provides information and a commentary on landmark trials presented at the European Society of Cardiology Heart Failure meeting held in June 2005, relevant to the pathophysiology, prevention and treatment of heart failure. All reports should be considered as preliminary data, as analyses may change in the final publication. The erythropoiesis stimulating protein, darbepoetin alfa, increased haemoglobin levels, improved quality of life and showed a trend for improved exercise duration in anaemic patients with symptomatic chronic heart failure. In the ECHOS study, the selective dopamine agonist nolomirole (CHF1035) showed no benefit in heart failure patients. Preliminary results of the ASCOT-BPLA study, which were reported at the American College of Cardiology meeting in March 2005, showed that in hypertensive patients, treatment with a calcium antagonist plus an ACE inhibitor was more effective at reducing cardiovascular outcomes than atenolol plus a diuretic. (c) 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.

引用

页码：937 / 939

页数：3

共 11 条

[1] Atenolol in hypertension: is it a wise choice? [J].

Carlberg, B ;

Samuelsson, O ;

Lindholm, LJ .

LANCET, 2004, 364 (9446) :1684-1689

[2]

CLELAND JGF, IN PRESS J CARDIOVAS

[3] Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? [J].

Cromie, N ;

Lee, C ;

Struthers, AD .

HEART, 2002, 87 (04) :377-378

[4] Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure [J].

Mancini, DM ;

Katz, SD ;

Lang, CC ;

LaManca, J ;

Hudaihed, A ;

Androne, AS .

CIRCULATION, 2003, 107 (02) :294-299

[5]

MORISCO C, 1995, J AM COLL CARDIOL S, V25, pA128

[6] Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial [J].

Sever, PS ;

Dahlöf, B ;

Poulter, NR ;

Wedel, H ;

Beevers, G ;

Caulfield, M ;

Collins, R ;

Kjeldsen, SE ;

Kristinsson, A ;

McInnes, GT ;

Mehlsen, J ;

Nieminen, M ;

O'Brien, E ;

Östergren, J .

LANCET, 2003, 361 (9364) :1149-1158

[7] The importance of anemia and its correction in the management of severe congestive heart failure [J].

Silverberg, DS ;

Wexler, D ;

Iaina, A .

EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (06) :681-686

[8] The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations [J].

Silverberg, DS ;

Wexler, D ;

Blum, M ;

Keren, G ;

Sheps, D ;

Leibovitch, E ;

Brosh, D ;

Laniado, S ;

Schwartz, D ;

Yachnin, T ;

Shapira, I ;

Gavish, D ;

Baruch, R ;

Koifman, B ;

Kaplan, C ;

Steinbruch, S ;

Iaina, A .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (07) :1737-1744

[9] The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study [J].

Silverberg, DS ;

Wexler, D ;

Sheps, D ;

Blum, M ;

Keren, G ;

Baruch, R ;

Schwartz, D ;

Yachnin, T ;

Steinbruch, S ;

Shapira, I ;

Laniado, S ;

Iaina, A .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (07) :1775-1780

[10] Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure [J].

Tjeerdsma, G ;

van Wijk, LM ;

Molhoek, GP ;

Boomsma, F ;

Haaksma, J ;

van Veldhuisen, DJ .

CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (02) :139-145

← 1 2 →